{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(3)"],"submitter":["Maria NI"],"funding":["Ministero dell’Istruzione, dell’Università e della Ricerca"],"pubmed_abstract":["The current, rapidly diversifying pandemic has accelerated the need for efficient and effective identification of potential drug candidates for COVID-19. Knowledge on host-immune response to SARS-CoV-2 infection, however, remains limited with few drugs approved to date. Viable strategies and tools are rapidly arising to address this, especially with repurposing of existing drugs offering significant promise. Here we introduce a systems biology tool, the PHENotype SIMulator, which -by leveraging available transcriptomic and proteomic databases-allows modeling of SARS-CoV-2 infection in host cells <i>in silico</i> to <i>i)</i> determine with high sensitivity and specificity (both>96%) the viral effects on cellular host-immune response, resulting in specific cellular SARS-CoV-2 signatures and <i>ii)</i> utilize these cell-specific signatures to identify promising repurposable therapeutics. Powered by this tool, coupled with domain expertise, we identify several potential COVID-19 drugs including methylprednisolone and metformin, and further discern key cellular SARS-CoV-2-affected pathways as potential druggable targets in COVID-19 pathogenesis."],"journal":["Heliyon"],"pagination":["e14115"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9986505"],"repository":["biostudies-literature"],"pubmed_title":["Application of the PHENotype SIMulator for rapid identification of potential candidates in effective COVID-19 drug repurposing."],"pmcid":["PMC9986505"],"pubmed_authors":["Rapicavoli RV","RxCOVEA Framework","Bischof E","Maria NI","Alaimo S","Mishra B","Pulvirenti A","Ferro A","Stasuzzo A","Broek JAC","Duits AJ"],"additional_accession":[]},"is_claimable":false,"name":"Application of the PHENotype SIMulator for rapid identification of potential candidates in effective COVID-19 drug repurposing.","description":"The current, rapidly diversifying pandemic has accelerated the need for efficient and effective identification of potential drug candidates for COVID-19. Knowledge on host-immune response to SARS-CoV-2 infection, however, remains limited with few drugs approved to date. Viable strategies and tools are rapidly arising to address this, especially with repurposing of existing drugs offering significant promise. Here we introduce a systems biology tool, the PHENotype SIMulator, which -by leveraging available transcriptomic and proteomic databases-allows modeling of SARS-CoV-2 infection in host cells <i>in silico</i> to <i>i)</i> determine with high sensitivity and specificity (both>96%) the viral effects on cellular host-immune response, resulting in specific cellular SARS-CoV-2 signatures and <i>ii)</i> utilize these cell-specific signatures to identify promising repurposable therapeutics. Powered by this tool, coupled with domain expertise, we identify several potential COVID-19 drugs including methylprednisolone and metformin, and further discern key cellular SARS-CoV-2-affected pathways as potential druggable targets in COVID-19 pathogenesis.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2026-06-23T03:19:42.463Z","creation":"2025-02-19T00:49:56.377Z"},"accession":"S-EPMC9986505","cross_references":{"pubmed":["36911878"],"doi":["10.1016/j.heliyon.2023.e14115"]}}